Janet Glassford is an Expert Quality Assessor at the MHRA with a special interest in ATMPs. Her role includes the assessment of ATMP marketing authorisations, early access assessments, innovation licensing pathway applications and the provision of scientific advice. Since joining the Agency in 2010, she has assessed a wide range of biological products, including numerous ATMPs (encompassing gene therapies, somatic cell therapy medicinal products and tissue engineered products). She has also contributed to various regulatory/scientific guidelines. Prior to becoming a regulator, she gained more than 18 years laboratory-based research experience. Her research interests and publications centred on the cell biology of haematological malignancies. During this time she acquired substantial hands-on experience of a wide variety of molecular and cell biological techniques relevant to ATMPs.